BR0014563A - Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica - Google Patents

Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica

Info

Publication number
BR0014563A
BR0014563A BR0014563-7A BR0014563A BR0014563A BR 0014563 A BR0014563 A BR 0014563A BR 0014563 A BR0014563 A BR 0014563A BR 0014563 A BR0014563 A BR 0014563A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
product
growth factor
anabolic
growth factors
Prior art date
Application number
BR0014563-7A
Other languages
English (en)
Inventor
Maarten Anne Hoijer
Robert Johan Joseph Hageman
Rudolf Leonardus Lodewi Smeets
Original Assignee
Nutricia Nv
Campina Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia Nv, Campina Bv filed Critical Nutricia Nv
Publication of BR0014563A publication Critical patent/BR0014563A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"USO DE FATOR DE CRESCIMENTO DE TRANSFORMAçãO BETA E FATORES DE CRESCIMENTO ANABóLICO, PRODUTO, E, COMPOSIçãO FARMACêUTICA". A presente invenção refere-se ao uso de fator de crescimento de transformação <225> (TGF-<225>) e fatores de crescimento anabólico (AGF) no tratamento e/ou prevenção de mau funcionamento ou doença da mucosa intestinal. Mais particularmente, a invenção refere-se ao tratamento e/ou prevenção de dano da mucosa intestinal como resultado de quimioterapia ou radioterapia ou de doenças inflamatórias do intestino com um produto compreendendo: a) uma primeira composição farmacêutica compreendendo TGF-<225> obtido por extração de um produto lácteo de mamífero na ausência substancial de fator de crescimento semelhante a insulina 1 (IGF-1), b) uma segunda composição farmacêutica compreendendo AGF na ausência substancial de TGF-<225>; em que a primeira e segunda composição são administradas seq³encialmente.
BR0014563-7A 1999-10-06 2000-10-06 Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica BR0014563A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL1999/000620 WO2001024812A1 (en) 1999-10-06 1999-10-06 USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
PCT/NL2000/000719 WO2001024813A1 (en) 1999-10-06 2000-10-06 Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa

Publications (1)

Publication Number Publication Date
BR0014563A true BR0014563A (pt) 2002-06-11

Family

ID=19866617

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014563-7A BR0014563A (pt) 1999-10-06 2000-10-06 Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica

Country Status (6)

Country Link
EP (2) EP1221965A1 (pt)
JP (1) JP2003510367A (pt)
CN (2) CN1299766C (pt)
AU (2) AU6232899A (pt)
BR (1) BR0014563A (pt)
WO (2) WO2001024812A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928186A1 (de) * 1989-08-25 1991-03-14 Niehoff Kg Maschf Greifvorrichtung fuer drahtspulen und dergleichen
FR2827290B1 (fr) * 2001-07-13 2004-07-09 Pierre Jouan Biotechnologies Sa Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques
GB0229658D0 (en) * 2002-12-20 2003-01-22 Cleeve Richard J Bird feed
TW201119585A (en) * 2003-11-12 2011-06-16 J Oil Mills Inc Body taste improver comprising long-chain highly unsaturated fatty acid and/or its ester
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7572474B2 (en) 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en) 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
US7744895B2 (en) * 2005-08-31 2010-06-29 Yamanashi University Methods of treating allergies using TGF-β1 and allergens
EP2049135A4 (en) * 2006-06-22 2009-12-30 Agennix Inc LACTOFERRINE AS RADIOPROTECTIVE AGENT
US8367354B2 (en) 2008-10-24 2013-02-05 Mead Johnson Nutrition Company Methods for determining the levels of TGF-β in a composition
US8350006B2 (en) 2008-10-24 2013-01-08 Mead Johnson Nutrition Company Methods for determining the bioactivity of TGF-β in a composition
US8986769B2 (en) 2008-10-24 2015-03-24 Mead Johnson Nutrition Company Methods for preserving endogenous TGF-β
AU2009333538B2 (en) * 2008-12-08 2014-09-11 Soligenix, Inc. Topically active steroids for use in radiation and chemotherapeutics injury
JP5552386B2 (ja) * 2010-07-09 2014-07-16 株式会社ファンケル Ｌ−アスコルビン酸−２−リン酸−６−脂肪酸凍結乾燥製剤及び化粧料
US20120171328A1 (en) 2011-01-05 2012-07-05 Dattatreya Banavara Composition comprising heat labile milk proteins and process for preparing same
BR112013030958B1 (pt) 2011-06-03 2022-02-08 Xoma Technology Ltd Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
EP2953974B1 (en) 2013-02-05 2017-12-20 EngMab Sàrl Bispecific antibodies against cd3epsilon and bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
US10167334B2 (en) 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
BR112018001955B1 (pt) 2015-08-03 2021-05-11 Engmab Sárl anticorpo monoclonal que se liga às células b humanas (bcma), composição farmacêutica e seu uso
HUE050556T2 (hu) 2015-08-17 2020-12-28 Janssen Pharmaceutica Nv Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai
DK4050034T3 (da) 2016-09-14 2024-06-03 Teneoone Inc Cd3-bindende antistoffer
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
IL300729A (en) 2016-12-21 2023-04-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
IL271194B1 (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
BR112019026803A2 (pt) 2017-06-20 2020-06-30 Teneoone, Inc. anticorpos apenas de cadeia pesada anti-bcma
PL423673A1 (pl) * 2017-12-01 2019-06-03 Lewandowska Agata Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis
MX2020012270A (es) 2018-05-16 2021-04-28 Janssen Biotech Inc Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t.
CN110051698A (zh) * 2019-03-18 2019-07-26 天津大学 基于微囊化处理的肠道原生菌基因改造的方法
TW202108628A (zh) 2019-06-14 2021-03-01 美商泰尼歐生物公司 與ｃ ｄ ２ ２ 及ｃ ｄ ３ 結合之多特異性重鏈抗體
KR20220068984A (ko) 2019-07-30 2022-05-26 상하이 한서 바이오메디컬 컴퍼니 리미티드 항-bcma 항체, 이의 항원-결합 단편 및 이의 의학적 용도
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
TW202330622A (zh) 2020-04-29 2023-08-01 美商泰尼歐生物公司 具有經修飾重鏈恆定區之多特異性重鏈抗體
US20230203161A1 (en) 2020-04-29 2023-06-29 Teneobio, Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
AU2021272291A1 (en) 2020-05-11 2023-02-02 Janssen Biotech, Inc. Methods for treating multiple myeloma
CA3189297A1 (en) 2020-06-30 2022-01-06 Nathan Trinklein Multi-specific antibodies binding to bcma
BR112023016121A2 (pt) 2021-02-16 2023-11-28 Janssen Pharmaceutica Nv Anticorpo triespecífico que direciona bcma, gprc5d e cd3
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3206784C2 (de) * 1982-02-25 1985-05-09 Pfrimmer & Co Pharmazeutische Werke Erlangen Gmbh, 8520 Erlangen Glutaminhaltige Zubereitungen für orale oder intravenöse Applikation
EP0269408A3 (en) * 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
US5451411A (en) * 1993-10-15 1995-09-19 University Of Washington Methods and compositions for the oral delivery of therapeutic agents
ES2123903T5 (es) * 1995-08-04 2011-02-22 N.V. Nutricia Composición nutritiva conteniendo fibra.
EP0852913A1 (en) * 1997-01-14 1998-07-15 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
NL1005677C2 (nl) * 1997-03-27 1998-09-29 Campina Melkunie Bv Werkwijze voor het winnen van groeifactoren, of een samenstelling die één of meer groeifactoren bevat, uit melk of een derivaat daarvan.
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung

Also Published As

Publication number Publication date
AU6232899A (en) 2001-05-10
EP1221965A1 (en) 2002-07-17
WO2001024812A1 (en) 2001-04-12
CN1299766C (zh) 2007-02-14
EP1779863A1 (en) 2007-05-02
CN1378458A (zh) 2002-11-06
WO2001024813A1 (en) 2001-04-12
CN1626239A (zh) 2005-06-15
AU1063201A (en) 2001-05-10
JP2003510367A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
BR0014563A (pt) Uso de fator de crescimento de transformação beta e fatores de crescimento anabólico, produto, e, composição farmacêutica
EP0224885B1 (en) Antitumor composition.
WO2011159071A2 (ko) 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
ES2869904T3 (es) Compuestos de Antrodia camphorata, método para prepararlos y uso de los mismos
CN100438862C (zh) 辅酶q作为活性成分的经粘膜给药的组合物
SE9704693L (sv) Användning av åtminstone en typ av xantofyller för framställning av ett humant eller verinärmedicinskt läkemedel för profylaktisk behandling av mastit hos däggdjursmammor
US6025400A (en) Compositions for treatment of antibiotic-resistant gram-positive bacterial infections and methods for using and preparing the same
Kelsey et al. Presence of azithromycin breast milk concentrations: a case report
CN102432620A (zh) 一种白藜芦醇四聚体化合物及其制备方法和应用
US7091336B2 (en) Lyophilized powder of lentinan and the process of preparation thereof
CS248712B2 (en) Production method of 6 alfa-methylcorticoids
US10022394B2 (en) Antiinfective composition
Rastegarpanah et al. Management of Human Ulcerative Colitis by Saturex”: A Randomized Controlled Trial
CN105055313B (zh) 一种畜禽使用的复方磺胺类纳米乳制剂及其制备方法
Wu et al. Burdock essence promotes gastrointestinal mucosal repair in ulcer patients
CN108853081B (zh) 穗花杉双黄酮在制备治疗鸡坏死性肠炎的药物中的用途
Midtvedt et al. Influence of antibiotics on microbial intestinal transformation of cholesterol to coprostanol in man
PT1510214E (pt) 8a¿azalidos como agentes antimicrobianos veterinários
US20210121439A1 (en) Medical use of tectorigenin in treatment of chicken necrotic enteritis
EP0443957A3 (en) New 17-spiro substituted steroid compounds, process for their preparation and intermediates of this process, their use as medicines and pharmaceutical preparations containing them
de Farias et al. Antibiotic-modifying activity of riachin, a non-cyanogenic cyanoglycoside extracted from Bauhinia pentandra
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
BR0112035A (pt) peptìdeos antimicrobianos de novispirin
AU4155700A (en) Use of fucosylated sialylated n-acetyl lactosamine carbohydrate structures for inhibition of bacterial adherence
CN101342187B (zh) 一种治疗痢疾的药物组合物

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.

B15K Others concerning applications: alteration of classification

Ipc: A61K 38/18 (2006.01), A61K 36/899 (2006.01), A61K